These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20078612)

  • 1. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
    Pau AK; Penzak SR; Boyd SD; McLaughlin M; Morse CG
    Pharmacotherapy; 2012 Jan; 32(1):e1-6. PubMed ID: 22392831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
    J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
    Antoniou T; Hasan S; Loutfy MR; Kovacs C; Brunetta J; Smith G; Halpenny R; La Porte C
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):e58-60. PubMed ID: 23328092
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
    Gonzalez-Serna A; McGovern RA; Harrigan PR; Vidal F; Poon AF; Ferrando-Martinez S; Abad MA; Genebat M; Leal M; Ruiz-Mateos E
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacokinetic of maraviroc].
    Peytavin G
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between alcohol and the HIV entry inhibitor Maraviroc.
    Gruber VA; Rainey PM; Lum PJ; Beatty GW; Aweeka FT; McCance-Katz EF
    J Int Assoc Provid AIDS Care; 2013; 12(6):375-7. PubMed ID: 23881910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
    Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.